In selecting Hospital for Special Surgery (HSS) for your orthopedic and rheumatologic care, you are entering a hospital with a rich tradition of innovation and education that has long established HSS as an internationally recognized center of excellence for musculoskeletal health care. If your doctor asks you to consider enrollment in a research study (clinical trial) as part of your care, you can be assured that this request is in keeping with the HSS mission of delivering healthcare of the highest quality.
Your participation in clinical research is a valuable contribution to medical science. It is the essential road to discovery of new and better health care, and it is the way that doctors and researchers translate new knowledge into safe and effective practices and procedures in medicine and surgery. As the leading academic center in musculoskeletal medicine, HSS is dedicated to the highest standards of clinical care, education, and research. Research is the engine that drives this academic excellence and the best patient care possible.
While most patients understand the importance of research and are inclined to participate, it is natural to have some concerns about joining a clinical trial. Among those questions that may come up are:
It is at this moment that the essential process of informed choice begins. For these concerns, and many more, you have a strong advocate protecting your rights and interests: the Hospital for Special Surgery Institutional Review Board (IRB).
The IRB watches over clinical research at HSS, with the primary responsibility of assuring that in the conduct of meaningful clinical research, the highest ethical standards and scientific integrity are maintained. And furthermore, that the rights, safety, and privacy of our research participants are protected at all times and without compromise.
Institutional Review Board oversight and regulatory review is provided by a panel of 12 full-time members and 10 alternates. The members are professionally diverse, consisting of doctors, nurses, and professional staff representing expertise in all areas of scientific review. Membership also includes non-scientists, lawyers, clergy, and members of the local community, who have no affiliation with Hospital for Special Surgery other than serving on the IRB panel of reviewers.
The IRB must review every HSS research protocol (the detailed document prepared by researchers outlining how the study will be conducted) that involves human subjects. After doing so, the board may approve, disapprove, modify, and suspend research as it sees fit. Once a clinical research study is approved, the IRB tracks any complications or adverse events that may occur. Severe adverse events that may jeopardize the safety of patients involved in a study are immediately identified and reported to the IRB. The result may be suspension of the research or modification to eliminate an identified risk.
All active research studies are subject to formal continuing review by the IRB panel, on an annual basis, or more frequently in studies that involve greater than minimal risk to those enrolled. The IRB also tracks journal publications and presentations at scientific meetings that result from completed IRB-approved research. It is important to understand that the IRB has final authority within the institution with regards to clinical research involving human participants.
Many of the protections for people involved in research may seem obvious and intuitive, but other areas of concern have emerged as the result of historical abuses. The guiding principles that are the core of research participant safeguards emerged after World War II, resulting in the Nuremberg Code of 1948, a foundation of five basic human protections in clinical research:
The Nuremberg Code standards coupled with subsequent experience and more insightful ethical values have resulted in eight fundamental principles that guide clinical research at HSS:
One of the most important requirements imposed by the IRB in research involving patients is the informed consent process. More than a written document that requires a patient’s signature, informed consent is a process that requires the proper setting, time, diligence, and clear explanation in obtaining consent.
The consent must be written in language that is clear and easily understood. It is important that the research candidate have time to read and understand the consent form, and to have all questions answered by an investigator or qualified hospital staff. The consent document must contain enough information about the research and its risks and benefits to allow the patient to make an informed decision regarding participation. Language and culture must be taken into consideration and, when necessary, translated consent documents must be used or an impartial translator/interpreter provided. Consent documents should include the following eight basic elements:
“The Privacy Rule,” known as HIPAA, the “Health Insurance Portability and Accountability Act,” became effective in April, 2003. It was established to protect the privacy of health information that you would expect to remain confidential, e.g., your medical record. The IRB must uphold HIPAA protection when considering how researchers may gain access to, use, and safeguard protected health information (PHI) necessary to conduct research. Patient information gained in the course of standard medical care cannot be reviewed or disseminated to anyone other than the patient’s physician without specific authorization by the patient, obtained at the time of written consent.
Everyone at HSS is dedicated to the highest standards of clinical research research that improves the lives of our patients. The HSS IRB is made up of knowledgeable and dedicated scientists and lay members who serve as an ethics review board for this research. When you agree to participate in a research study at HSS, you can rest assured that the Institutional Review Board is maintaining a constant vigilance to protect your rights, safety, and privacy.
Reviewed: 6/30/2009 Published: 5/19/2008